For Lambert Eaton Myasthenic Syndrome (LEMS). This high cost drug is likely to require a full HTA due to significant budget impact.
|07/11/2011||09/12/2011||Full Pharmacoeconomic Evaluation Recommended.|
|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of Lambert Eaton Myasthenic Syndrome (LEMS)|
|Rapid review commissioned||07/11/2011|
|Rapid review completed||09/12/2011|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|